Published in Clin Cardiol on May 31, 2012
Clinician's guide to the updated ABCs of cardiovascular disease prevention. J Am Heart Assoc (2014) 0.82
Patients' empowerment, physicians' perceptions, and achievement of therapeutic goals in patients with type 1 and type 2 diabetes mellitus in Mexico. Patient Prefer Adherence (2016) 0.75
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med (2006) 18.25
Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med (2012) 13.59
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. N Engl J Med (2014) 10.66
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med (2014) 10.54
Clinical end points in coronary stent trials: a case for standardized definitions. Circulation (2007) 10.31
Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med (2006) 8.74
Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med (2015) 8.69
Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med (2008) 8.39
A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA (2004) 7.32
Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med (2011) 7.30
Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation (2011) 6.36
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29
Possible Subclinical Leaflet Thrombosis in Bioprosthetic Aortic Valves. N Engl J Med (2015) 6.28
Troponin and Cardiac Events in Stable Ischemic Heart Disease and Diabetes. N Engl J Med (2015) 5.81
One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA (2007) 5.61
Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ (2013) 5.08
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med (2006) 5.07
Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 5.03
International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA (2006) 5.00
β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA (2012) 4.92
Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med (2011) 4.81
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med (2010) 4.73
Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet (2010) 4.72
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med (2012) 4.49
Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation (2007) 4.24
Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med (2013) 4.16
Bare metal stent restenosis is not a benign clinical entity. Am Heart J (2006) 3.39
Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation (2011) 3.30
Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost (2011) 3.16
Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation (2012) 3.14
Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol (2005) 3.05
Role of aspiration and mechanical thrombectomy in patients with acute myocardial infarction undergoing primary angioplasty: an updated meta-analysis of randomized trials. J Am Coll Cardiol (2013) 2.99
Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med (2014) 2.90
Grading scale for prediction of outcome in primary intracerebral hemorrhages. Stroke (2007) 2.85
Carotid artery stenting vs carotid endarterectomy: meta-analysis and diversity-adjusted trial sequential analysis of randomized trials. Arch Neurol (2010) 2.83
Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J (2005) 2.80
CPAP versus oxygen in obstructive sleep apnea. N Engl J Med (2014) 2.75
ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol (2008) 2.67
Predictors of adherence to performance measures in patients with acute myocardial infarction. Am J Med (2012) 2.64
Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA (2013) 2.62
Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol (2005) 2.59
Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol (2007) 2.56
Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol (2010) 2.55
Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet (2012) 2.53
Living alone and cardiovascular risk in outpatients at risk of or with atherothrombosis. Arch Intern Med (2012) 2.53
Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med (2010) 2.52
Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med (2009) 2.52
Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med (2006) 2.38
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. Eur Heart J (2007) 2.31
Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study. Arch Intern Med (2003) 2.29
Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke (2004) 2.24
Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high-risk group: insights from the Global Registry of Acute Coronary Events. Chest (2004) 2.19
Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET). J Am Coll Cardiol (2003) 2.17
Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis. Circulation (2011) 2.17
Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J (2008) 2.09
Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation (2008) 2.05
Using statins to treat inflammation in acute coronary syndromes: Are we there yet? Cleve Clin J Med (2006) 2.05
Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation (2012) 2.03
Renal failure after percutaneous coronary intervention is associated with high mortality. Catheter Cardiovasc Interv (2005) 2.00
Usefulness of an elevated neutrophil to lymphocyte ratio in predicting long-term mortality after percutaneous coronary intervention. Am J Cardiol (2006) 2.00
Discharge to a skilled nursing facility and subsequent clinical outcomes among older patients hospitalized for heart failure. Circ Heart Fail (2011) 1.99
Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of Thrombin–Coronary Artery Disease Trial. Circulation (2011) 1.96
Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J (2012) 1.95
Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol (2006) 1.94
Changes in myocardial infarction guideline adherence as a function of patient risk: an end to paradoxical care? J Am Coll Cardiol (2011) 1.92
Role of adjunctive thrombectomy and embolic protection devices in acute myocardial infarction: a comprehensive meta-analysis of randomized trials. Eur Heart J (2008) 1.92
[Effect of educational level on the prognosis of acute myocardial infarction]. Rev Med Chil (2015) 1.92
Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry. Eur Heart J (2009) 1.84
Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation (2012) 1.84
Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care (2013) 1.83
Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J (2009) 1.80
Smoking, clopidogrel, and mortality in patients with established cardiovascular disease. Circulation (2009) 1.77
Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med (2009) 1.76
Strategies used by hospitals to improve speed of tissue-type plasminogen activator treatment in acute ischemic stroke. Stroke (2014) 1.76
Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur Heart J (2010) 1.74
Meta-analysis of mortality in dialysis patients with an implantable cardioverter defibrillator. Am J Cardiol (2009) 1.74
What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis. J Am Coll Cardiol (2005) 1.72